BioNTech Clocks Q3 Sales Of €6B; Raises FY21 COVID-19 Vax Sales Outlook

BioNTech SE BNTX reports Q3 FY21 revenues of €6.08 billion compared to €67.5 million a year ago, mainly due to rapid increases in the supply and sales of the COVID-19 vaccine worldwide.
As of November 2, BioNTech and its partner Pfizer Inc PFE have shipped over two billion doses of its COVID-19 vaccine (BNT162b2).
BioNTech generated an operating income of €4.7 billion, a turnaround from a loss of €186.4 million a year ago.
Net profit also saw a massive growth to €3.2 billion versus a loss of €210 million in Q2 2020. Cash and cash equivalents stood at €2.4 billion.
Outlook: BioNTech estimates FY21 COVID-19 vaccine revenues of €16 billion - €17 billion, based on 2.5 billion doses. Earlier, the Company expected sales of around €15.5 billion.
It reaffirmed the FY21 manufacturing capacity of 3 billion doses and up to 4 billion doses for 2022.
The EC authorized a new formulation of BNT162b2 that allows for longer storage, as vials can be stored for 10 weeks at refrigerator temperatures from 2°C to 8°C.
After the first puncture, vials can be stored and transported at 2°C to 30°C and used within 12 hours.
Price Action: BNTX shares are trading 6.76% higher at $$259 during the premarket session on Tuesday's last check.
Photo by x3 from Pixabay